1% rule (aviation medicine)

Last updated

In aviation medicine, the 1% rule is a risk threshold that is applied to the medical fitness of pilots. The 1% rule states that a 1% per annum risk (See also risk management) of medical incapacitation is the threshold between acceptable and unacceptable. In other words:

Applying this 1 percent rule would result in an airline pilot being denied a medical certificate if their risk of a medical incapacitation (e.g. heart attack, convulsion, stroke, faint etc) was determined as being greater than 1% during the year.

This 1 percent rule began in the late 1980s and early 1990s in a series of British and then European aviation cardiology workshops. The application of this "1 percent rule" has subsequently spread beyond the domain of aviation cardiology to all potential causes of medical incapacitation.

The reasoning that was used in the development of the original aviation medical 1 percent rule is well described in Flight Safety and Medical Incapacitation Risk of Airline Pilots (see references). In this article the authors argue that changes in the underlying assumptions, that were the basis of the 1 percent rule, have been such that a 2 percent rule may be an appropriate modern analogue.

The application of this one percent rule is controversial. The civil aviation regulatory authorities of some nations employ such numerical risk thresholds while others do not. Of those that use numerical risk criteria there are differences in the levels of measured / calculated risk that are applied (1% per annum, 2% per annum etc.). There is also debate concerning the application of population statistics to an individual pilot and the utility and validity of the risk screening tools that are used by the civil aviation regulatory authorities (e.g. data from the Framingham Heart Study).

Related Research Articles

An ejection fraction (EF) is the volumetric fraction of fluid ejected from a chamber with each contraction. It can refer to the cardiac atrium, ventricle, gall bladder, or leg veins, although if unspecified it usually refers to the left ventricle of the heart. EF is widely used as a measure of the pumping efficiency of the heart and is used to classify heart failure types. It is also used as an indicator of the severity of heart failure, although it has recognized limitations.

<span class="mw-page-title-main">Hypercholesterolemia</span> High levels of cholesterol in the blood

Hypercholesterolemia, also called high cholesterol, is the presence of high levels of cholesterol in the blood. It is a form of hyperlipidemia, hyperlipoproteinemia, and dyslipidemia.

<span class="mw-page-title-main">Aviation medicine</span> Medicine for pilots, aircrews, or astronauts

Aviation medicine, also called flight medicine or aerospace medicine, is a preventive or occupational medicine in which the patients/subjects are pilots, aircrews, or astronauts. The specialty strives to treat or prevent conditions to which aircrews are particularly susceptible, applies medical knowledge to the human factors in aviation and is thus a critical component of aviation safety. A military practitioner of aviation medicine may be called a flight surgeon and a civilian practitioner is an aviation medical examiner. One of the biggest differences between the military and civilian flight doctors is the military flight surgeon's requirement to log flight hours.

<span class="mw-page-title-main">Unstable angina</span> Chest pain due to heart muscles that is easily provoked

Unstable angina is a type of angina pectoris that is irregular or more easily provoked. It is classified as a type of acute coronary syndrome.

The lipid hypothesis is a medical theory postulating a link between blood cholesterol levels and the occurrence of cardiovascular disease. A summary from 1976 described it as: "measures used to lower the plasma lipids in patients with hyperlipidemia will lead to reductions in new events of coronary heart disease". It states, more concisely, that "decreasing blood cholesterol [...] significantly reduces coronary heart disease".

The CHADS2 score and its updated version, the CHA2DS2-VASc score, are clinical prediction rules for estimating the risk of stroke in people with non-rheumatic atrial fibrillation (AF), a common and serious heart arrhythmia associated with thromboembolic stroke. Such a score is used to determine whether or not treatment is required with anticoagulation therapy or antiplatelet therapy, since AF can cause stasis of blood in the upper heart chambers, leading to the formation of a mural thrombus that can dislodge into the blood flow, reach the brain, cut off supply to the brain, and cause a stroke.

<span class="mw-page-title-main">Ticagrelor</span> Coronary medication

Ticagrelor, sold under the brand name Brilinta among others, is a medication used for the prevention of stroke, heart attack and other events in people with acute coronary syndrome, meaning problems with blood supply in the coronary arteries. It acts as a platelet aggregation inhibitor by antagonising the P2Y12 receptor. The drug is produced by AstraZeneca.

<span class="mw-page-title-main">Myocardial infarction</span> Interruption of cardiac blood supply

A myocardial infarction (MI), commonly known as a heart attack, occurs when blood flow decreases or stops in one of the coronary arteries of the heart, causing infarction to the heart muscle. The most common symptom is retrosternal chest pain or discomfort that classically radiates to the left shoulder, arm, or jaw. The pain may occasionally feel like heartburn. This is the dangerous type of Acute coronary syndrome.

<span class="mw-page-title-main">Atrial fibrillation</span> Irregular beating of the atria of the heart

Atrial fibrillation is an abnormal heart rhythm (arrhythmia) characterized by rapid and irregular beating of the atrial chambers of the heart. It often begins as short periods of abnormal beating, which become longer or continuous over time. It may also start as other forms of arrhythmia such as atrial flutter that then transform into AF.

John Eric Deanfield is a British professor of cardiology and past Olympic fencer.

Salim Yusuf is an Indian-born Canadian physician, the Marion W. Burke Chair in Cardiovascular Disease at McMaster University Medical School. He is a cardiologist and epidemiologist, and is well known for his cardiology-related clinical trial research. He also formerly served as president of the World Heart Federation. Yusuf has criticized the Dietary Guidelines for Americans and disputes the scientific consensus on dietary sodium and saturated fat intake.

<span class="mw-page-title-main">James S. Forrester (cardiologist)</span> American cardiologist

James S. Forrester III is an American cardiologist. Born in Philadelphia, Pennsylvania, he received his medical training at the University of Pennsylvania, UCLA, and Harvard University. During the 1970s through 1990s, his research led to three major advancements in the practice of cardiology. Later in his career, he would return to UCLA, this time as a professor, while simultaneously being the Chief of the Division of Cardiology at Cedars-Sinai Medical Center. Forrester has published hundreds of papers and manuscripts dealing with the subject of cardiology, and is the recipient of numerous awards, including being the second person to ever receive the Lifetime Achievement Award of the American College of Cardiology in 2009.

Dan Tunstall Pedoe – "Dr Dan" and the "father of marathon medicine" – was a cardiologist who developed pioneering methods of diagnosis. He is popularly known for his contributions to sports medicine, particularly his support of the London Marathon.

Professor Aly Saad, is a professor of cardiology at Zagazig University and a member of the higher committee of promotion of professors and assistant professors of cardiovascular diseases and critical care subspecialty in Egypt.

Ulf Landmesser is a German specialist for cardiology and internal medicine. He is professor at the Institute for Health Research in Berlin and Head of the Medical Clinic of Cardiology at the Charité in Berlin. Landmesser is known for his work on coronary interventions and modern methods of catheter-based heart valve therapy.

Remnant cholesterol, also known as remnant lipoprotein and triglyceride-rich lipoprotein cholesterol is an atherogenic lipoprotein composed primarily of very low-density lipoprotein (VLDL) and intermediate-density lipoprotein (IDL) with chylomicron remnants. Elevated remnant cholesterol is associated with increased risk of atherosclerotic cardiovascular disease and stroke.

<span class="mw-page-title-main">Stefan D. Anker</span> German cardiologist

Stefan D. Anker is a German cariologist who is Head of Field “Tissue Homeostasis and Cachexia" at Charité University, Berlin, Germany. Previously, he was Professor of Innovative Clinical Trials at University Medical Center Göttingen in Germany. The main focus of the Innovative Clinical Trials department was research in the field of chronic heart failure, including the development and clinical testing of new therapies.

<span class="mw-page-title-main">Sports cardiology</span>

Sports cardiology is an emerging subspecialty field of Cardiology. It may also be considered a subspecialty field of Sports medicine, or alternatively a hybrid subspecialty that spans cardiology and sports medicine. Emergency medicine is another medical specialty that has some overlap with Sports Cardiology. Sports cardiology is now considered to be a distinct subspecialty in Europe and the USA, with a core curriculum developed in both regions. In Europe it has traditionally been grouped under Preventive Cardiology, but the subspecialty of Sports Cardiology is now considered a distinct field. In the USA, it has developed from being a special interest area to a distinct subspecialty as well.

Thomas F. Lüscher is a Swiss professor of cardiology, director of research, education and development and a consultant cardiologist at the Royal Brompton and Harefield NHS Foundation Trust and Imperial College London, and director of the Center for Molecular Cardiology at the University of Zurich.

<span class="mw-page-title-main">Roberto Ferrari (cardiologist)</span> Italian Cardiologist

Roberto Ferrari is an Italian cardiologist who holds the position of Emeritus Professor at the University of Ferrara, where besides he was the chair of the Cardiology in the School of Medicine until the 2019–2020 academic year.

References

    Further reading